Cooper Companies (NASDAQ:COO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS
Cooper Companies (NASDAQ:COO) reported quarterly EPS of $1.21, above the $1.10 consensus, and revenue of $1.08 billion versus $1.05 billion, according to FiscalAI. The company updated FY 2026 guidance to $4.580–$4.660 EPS. Shares rose to $62.02 midday. Analysts cited include Barclays ($103) and Goldman Sachs ($61).
How this was made
The 30-second read
Why it matters
The combination of an EPS/revenue beat and guidance update is the key catalyst; however, the guidance midpoint being slightly below the Street estimate can temper the magnitude of the re-rating.
Market read
Earnings beat plus FY2026 guidance update is likely to influence near-term positioning and analyst revisions, with upside potentially capped by guidance vs consensus midpoint.
What to watch
The article doesn’t break out segment performance (CooperVision vs CooperSurgical) or margin drivers; those details often determine whether the beat translates into sustained multiple expansion.
Background
Cooper Companies is a global medical device firm operating through CooperVision and CooperSurgical, and this release includes both quarterly results and an FY2026 EPS guidance update.
Ticker impact
Cooper Companies reported $1.21 EPS vs $1.10 consensus and raised FY2026 guidance to 4.58–4.66 EPS, driving the earnings re-rate narrative.
Moderately positive bias for the next sessions; follow-through depends on whether investors focus on the beat vs the guidance midpoint vs Street estimate.
The article provides concrete earnings and guidance datapoints (EPS/revenue beats; guidance range and midpoint vs Street 4.62), which typically move the stock, but guidance is only slightly below the midpoint expectation, capping upside.
Market effects
Positive read-through for medical device demand/profitability expectations, though the article is single-name and lacks peer-specific guidance changes.
Primarily US-focused via NASDAQ-listed earnings; limited explicit cross-regional effects.
Global medical device demand signal, but no international regulatory/contract developments cited.
Counterpoint
Investors may fade the move if they anchor on the FY2026 guidance midpoint (4.62) being slightly below the Street estimate, implying limited incremental upside.
Key entities
- companyCooper Companies
NASDAQ-listed medical device company reporting quarterly EPS/revenue and updating FY2026 EPS guidance.
